#United States #New York #Levi & Korsinsky #Humacyte #Securities Fraud

Reminder for Humacyte, Inc. Shareholders: Lead Plaintiff Deadline Approaching

On December 31, 2024, Levi & Korsinsky, LLP informed investors of Humacyte, Inc. (NASDAQ: HUMA) regarding an important class action lawsuit related to alleged securities fraud. Investors affected between May 10, 2024, and October 17, 2024, are particularly urged to respond, with a lead plaintiff appointment deadline set for January 17, 2025.

What Does the Lawsuit Entail?

The filed complaint claims that the defendants made misleading statements and concealed critical information regarding the company's Durham, North Carolina facility. Specific allegations include that the facility did not adhere to good manufacturing practices, which encompasses crucial areas such as quality assurance and microbial testing. Furthermore, it was indicated that the FDA's review of Humacyte's biologics license application would be postponed due to the necessity of remediation of these deficiencies.

The resulting risks potentially jeopardized FDA approval for Humacyte's acellular tissue-engineered vascular vessel designed for trauma applications. The lawsuit thus posits that the positive statements regarding the company's operational health were materially misleading and not based on a reasonable foundation.

Who Can Join the Case?

For investors who suffered losses during this relevant timeframe, it’s crucial to note that they have the opportunity to ask the court to appoint them as the lead plaintiff. However, serving as a lead plaintiff is not a prerequisite for participating in any potential recovery. Interested shareholders are not required to incur any out-of-pocket expenses or fees for joining the class action; participation does not come with financial obligations.

Solid Track Record of Levi & Korsinsky

Levi & Korsinsky has established credibility with over 20 years of experience, yielding hundreds of millions of dollars in recoveries for shareholders. The firm specializes in complex securities litigation and provides dedicated support from a team of over 70 professionals. Consistently recognized, for seven consecutive years, they ranked in the top 50 firms for securities litigation according to ISS Securities Class Action Services.

Next Steps for Affected Shareholders

Shareholders who believe they are eligible to partake in this lawsuit should consider reaching out to the law firm promptly to avoid missing deadlines. You can get in touch with attorney Joseph E. Levi via email at email protected] or through telephone at (212) 363-7500 to discuss participation details. Additional information can also be found by following this link: [humacyte lawsuit submission.

As shareholders in Humacyte, understanding these developments can be crucial in navigating the next steps in what could be a significant legal recovery process. Ensure that you act before the deadline to safeguard your interests.